ARCT: צמיחה צפויה ברווח למניה לשנה הבאה arcturusrx.com
The complex transportation of mRNA drugs in cryocontainers requires significant cold chain expenditures. The projected EPS growth for next year confirms this trend, fixing the metric at -19.40. Stable cash flows and partner payments support Arcturus Therapeutics (ARCT), while its strong reputation for developing innovative vaccines ensures the trust of the medical community.
פילוחים אנליטיים ודוחות נתונים של חברת Arcturus Therapeutics Inc (ARCT)
This indicator reflects the consensus forecast for the change in earnings per share, calculated as the difference between expected and current earnings. By analyzing the target growth rate of earnings per share, investors assess the probability of commercializing mRNA therapies for Arcturus Therapeutics (ARCT), where the chart's dynamics depend directly on clinical trial results and the prospects of government contracts.
